Recent studies collectively demonstrated that given a FAP-targeting moiety of the right specificity, in combination with targeting of tumour antigen [75] or immune checkpoints [42], and optimal modes of delivery, FAP targeting may potentially result in clinically beneficial tumour-specific outcome with minimal off-tumour on-target toxicity. This evidence concerns the gene FAP and neoplasm.